二十碳五烯酸降低溃疡性结肠炎患者粪便钙卫蛋白水平并预防复发
这项安慰剂对照试验纳入60例部分Mayo评分<2且粪便钙卫蛋白≥150 μg/g的溃疡性结肠炎患者,随机给予EPA-FFA 500 mg每日两次或安慰剂治疗6个月。EPA-FFA组63.3%达到粪便钙卫蛋白较基线下降100分的主要终点,高于安慰剂组的13.3%(OR 12.0,95%CI 3.12-46.24,P<.001),且无严重不良事件。
要点
- EPA-FFA组19/30(63.3%)达到粪便钙卫蛋白下降100分,安慰剂组4/30(13.3%)(OR 12.0,P<.001)。
- EPA-FFA组23/30(76.7%)维持临床缓解,安慰剂组15/30(50%)(OR 3.29,P=.035)。
- 研究期间未观察到严重不良事件。
核心结论
- 在60例溃疡性结肠炎患者的安慰剂对照试验中,给予EPA-FFA 6个月可降低粪便钙卫蛋白水平,且无严重不良事件。
- 作者认为该药可能用于诱导和维持溃疡性结肠炎患者的无症状缓解。
研究设计与样本
- 安慰剂对照试验,2014年6月至2016年5月纳入60例溃疡性结肠炎患者。
- 入组条件为部分Mayo评分<2、粪便钙卫蛋白≥150 μg/g,且此前至少3个月维持稳定治疗。
- 患者按1:1随机接受EPA-FFA 500 mg每日两次或安慰剂治疗6个月,基线时行结肠镜检查。
主要发现
- 主要终点为6个月时粪便钙卫蛋白较基线下降100分,EPA-FFA组19/30(63.3%)达到 vs 安慰剂组4/30(13.3%)(OR 12.0,95%CI 3.12-46.24,P<.001)。
- 次要终点为6个月时维持临床缓解,EPA-FFA组23/30(76.7%)达到 vs 安慰剂组15/30(50%)(OR 3.29,95%CI 1.08-9.95,P=.035)。
- 未观察到严重不良事件。
临床怎么用
- 作者认为EPA-FFA可能用于诱导和维持溃疡性结肠炎患者的无症状缓解。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: High fecal levels of calprotectin indicate mucosal inflammation and have been shown to predict relapse in patients with ulcerative colitis (UC). Eicosapentaenoic acid (EPA), the major component of n-3 fish oil, has anti-inflammatory properties in patients with chronic inflammatory disorders. We performed a placebo-controlled trial of patients with UC at risk of relapse to determine the ability of the free fatty acid form of EPA (EPA-FFA) to reduce intestinal inflammation, using fecal level of calprotectin as a marker. METHODS: From June 2014 to May 2016, 60 patients with UC with a partial Mayo score < 2 and fecal calprotectin ≥150 μg/g, in stable therapy for at least the 3 previous months, were randomly assigned to groups (1:1) given either EPA-FFA (500 mg, twice daily) or placebo for 6 months. A colonoscopy was performed at baseline. Clinical assessments and measurements of fecal calprotectin were made at baseline, at study months 3 and 6, or the time of clinical relapse. Patients with a relapse of UC underwent a second colonoscopy. The primary end point was a 100-point reduction in fecal levels of calprotectin at 6 months from the baseline value; the secondary end point was maintenance of clinical remission at 6 months. RESULTS: The primary end point was achieved by 19 of 30 patients (63.3%) in the EPA-FFA group vs 4 of 30 patients (13.3%) in the placebo group (odds ratio, 12.0; 95% CI, 3.12-46.24; P < .001). The secondary end point was achieved by 23 of 30 patients (76.7%) in the EPA-FFA group vs 15 of 30 (50%) patients in the placebo group (OR, 3.29; 95% CI, 1.08-9.95; P = .035). No serious adverse events were observed. CONCLUSIONS: In a placebo-controlled trial of 60 patients with UC, we found 6 months' administration of EPA-FFA to reduce fecal levels of calprotectin with no serious adverse events. This agent might be used to induce and maintain symptom-free remission in patients with UC. ClinicalTrials.gov number: NCT02179372.
引用
- Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018. PMID: 29391271. doi:10.1016/j.cgh.2018.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。